Evolva receives additional funds

Reinach, Switzerland, 2 July 2010 – Evolva Holding SA (SIX: EVE) today announces that Ventureast Trustee Company (P) Limited (“Ventureast”) and APIDC Venture Capital (P) Limited (“APIDC”) have provided CHF 3.5 million of fresh funds to Evolva. This is in line with the commitment that the two investors made in December 2009.

As agreed in December 2009, the investors have provided the additional funds to Evolva’s Indian subsidiary, in which they already own a minority participation. This participation is expected to be converted into shares in Evolva Holding SA within the next 12 months, such that Evolva India will become a 100%-subsidiary in the Evolva group.

Evolva India works on the creation of gene libraries and synthetic and analytical chemistry. In addition, it works on industrial projects and informatics. At the end of 2009, Evolva India employed 23 people.

The additional funds as well as the conversion were announced in the Listing Prospectus of Evolva Holding SA of December 2009. The shareholders of Evolva Holding SA have approved the authorised capital, required for the intended conversion.

-- ends --

Contact Details

Download PDF

• English
• German

About Evolva Holding SA

Evolva's proprietary discovery technology platform uses a “disruptive” technological approach to the creation of novel small compounds that differs sharply from the prevailing synthetic chemistry and protein engineering approaches in the pharmaceutical industry today. Based on this technology, Evolva has a number of discovery and pre-clinical partnerships which in 2009 generated revenues of CHF 18.9 million. Evolva also has an attractive pipeline of compounds – one drug candidate (for renal and cardiovascular diseases) entered Phase I at the beginning of 2009, and two others (an anti-fungal and an anti-viral) are in late preclinical stages. Evolva is listed in the main standard of the SIX Swiss Exchange with the ticker EVE. For more information see www.evolva.com.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.